| 12.49 0 (0%) | 02-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.59 | 1-year : | 17.04 |
| Resists | First : | 12.49 | Second : | 14.59 |
| Pivot price | 12.45  |
|||
| Supports | First : | 12.37 |
Second : | 12.3 |
| MAs | MA(5) : | 12.48 |
MA(20) : | 12.43 |
| MA(100) : | 11.67 |
MA(250) : | 9.62 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 95.9 |
D(3) : | 93.3 |
| RSI | RSI(14): 66.3 | |||
| 52-week | High : | 12.49 | Low : | 5.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CDMO ] has closed below upper band by 20.5%. Bollinger Bands are 89.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.5 - 12.56 | 12.56 - 12.61 |
| Low: | 12.34 - 12.41 | 12.41 - 12.48 |
| Close: | 12.38 - 12.49 | 12.49 - 12.59 |
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Mon, 15 Sep 2025
Avid Bioservices Welcomes Kenneth Bilenberg as new CEO - PR Newswire
Mon, 28 Apr 2025
Avid Bioservices to Be Acquired by GHO Capital and Ampersand - CHEManager
Mon, 17 Feb 2025
Avid Bioservices Goes Private Via $1.1 Billion Sale to PE Firms - Orange County Business Journal
Wed, 05 Feb 2025
Major CDMO Acquisition: GHO Capital Snaps Up Avid Bioservices at 62% Premium - Stock Titan
Wed, 05 Feb 2025
Avid Bioservices, Inc. Provides Notice of Fundamental - GlobeNewswire
Sat, 01 Feb 2025
Avid Bioservices’ $12.50 per Share Merger Agreement: Key Takeaways and Stockholder Guide (CDMO) - tradingcalendar.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 11,640 (K) |
| Shares Short P.Month | 13,510 (K) |
| EPS | -2.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.95 |
| Profit Margin | -101.3 % |
| Operating Margin | -6.2 % |
| Return on Assets (ttm) | -3.1 % |
| Return on Equity (ttm) | -115.9 % |
| Qtrly Rev. Growth | 6.5 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 2.22 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 8 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -5.19 |
| PEG Ratio | 0 |
| Price to Book value | 13.01 |
| Price to Sales | 5.61 |
| Price to Cash Flow | 106.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|